CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients

Abstract In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuation, predominately in haploidentical HCT recipients, without any associations with CMV-DNAemia under letermovir.

[1]  P. Lescuyer,et al.  Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients , 2022, Antimicrobial agents and chemotherapy.

[2]  K. Akashi,et al.  Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis , 2022, International Journal of Hematology.

[3]  F. Gao,et al.  Letermovir discontinuation at D+100 after Allogeneic Stem Cell Transplant is associated with increased CMV-related mortality. , 2022, Transplantation and cellular therapy.

[4]  Tomoki Ito,et al.  Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis. , 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[5]  G. Papanicolaou,et al.  American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. , 2021, Transplantation and cellular therapy.

[6]  C. van Delden,et al.  Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients , 2021, Immunity, inflammation and disease.

[7]  E. Shpall,et al.  Refractory and Resistant Cytomegalovirus after Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  C. van Delden,et al.  Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study , 2021, Vaccines.

[9]  J. Schiffer,et al.  Cytomegalovirus-specific T-cell Reconstitution following Letermovir Prophylaxis after Hematopoietic Cell Transplantation. , 2021, Blood.

[10]  J. Bourhis,et al.  Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study , 2020, Bone Marrow Transplantation.

[11]  F. Baldanti,et al.  Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  Ji Lin,et al.  Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies , 2020, Annals of Hematology.

[13]  P. Hari,et al.  Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  N. Kröger,et al.  Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. , 2020, The Lancet. Haematology.

[15]  R. Leavitt,et al.  Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  C. Teng,et al.  Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[17]  E. Shpall,et al.  The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients , 2018, The Journal of infectious diseases.

[18]  Michael Boeckh,et al.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation , 2017, The New England journal of medicine.

[19]  E. Atilla,et al.  A review of infectious complications after haploidentical hematopoietic stem cell transplantations , 2017, Infection.

[20]  W. Leisenring,et al.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. , 2002, Blood.